What are the recommended usage and dosage of Pimitinib?

Pimitespib is a novel HSP90 inhibitor that has been approved in Japan for the treatment of patients with advanced gastrointestinal stromal tumors (GIST) who have failed multiple lines of tyrosine kinase inhibitor (TKI) therapy. There are clear and strict specifications for the use and dosage of this drug to ensure maximum efficacy and reduce the occurrence of adverse reactions. The standard recommended dose is 160 mg per day, administered orally, and should be taken on an empty stomach, that is, without eating for at least one hour before and after taking the drug. Patients should take medication for 5 days and then stop taking it for 2 days to form a cycle of "5 days of medication + 2 days of rest". This intermittent administration method can help reduce the cytotoxicity caused by HSP90 inhibition, especially the impact on liver function and gastrointestinal tract.

The dosage form of pimetibib is usually an oral tablet, which is recommended to be taken at the same time every day to maintain a stable blood concentration. Treatment should be continued until disease progression occurs or until toxicity is intolerable to the patient. It is worth emphasizing that the patient's blood routine, liver and kidney function, and electrocardiogram need to be closely monitored during treatment, because although the drug is relatively well tolerated, common adverse reactions such as diarrhea, nausea, fatigue, and elevated ALT/AST may still occur. A very small number of patients may experience QT interval prolongation or ocular toxicity. If a grade ≥2 toxic reaction occurs, the medication should be suspended and supportive treatment should be provided. If necessary, the dose should be reduced to 120 mg or 80 mg according to the specific situation.

In addition, for elderly or underweight patients, the initial dose may be adjusted as appropriate. There is currently insufficient evidence to support its safety in patients with severe hepatic and renal insufficiency. Therefore, such patients need to weigh the risks and benefits when using it, and administer it with caution under the close supervision of doctors. In clinical practice, pimetibi may also be used in combination with other targeted drugs or immunotherapy, but when used in combination, more attention needs to be paid to drug-drug interactions and adverse reaction superposition issues.

Reference materials:https://en.wikipedia.org/wiki/Pimitespib